The Australian Pharmaceutical Benefits Scheme (PBS) has approved the listing of Trimbow 200/6/10 (Trimbow) for the maintenance treatment of asthma from January 1 2023. The medication is manufactured by Chiesi Australia, branded Trimbow.
Asthma Australia is pleased that adults with asthma in Australia will now have access to Trimbow as a more cost-effective specialised medication to assist with their condition. The listing on the PBS means those who benefit from Trimbow can access the medication at a considerably reduced cost, courtesy of subsidies from the Australian Government.
The medication is taken by inhalation, is available from a pharmacist and requires a prescription.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
For more details, you can read our media release with more information.